May 8 |
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
|
May 7 |
GlycoMimetics reports data from Phase III AML treatment trial
|
May 6 |
GlycoMimetics plummets 77% as phase 3 leukemia therapy uproleselan fails
|
May 6 |
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
Apr 30 |
GlycoMimetics: Is No News Bad News?
|
Apr 28 |
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
|
Apr 25 |
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
|
Apr 1 |
Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term
|